Overview

A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL

Status:
Active, not recruiting

Trial end date:
2023-10-01

Target enrollment:

Participant gender:

Summary

This research study will be evaluating the safety and efficacy of a study drug called TGR-1202 in combination with a known drug ibrutinib, also known as Imbruvica, as a possible treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Mantle Cell Lymphoma (MCL) that has come back or that has not responded to standard treatment.

Phase:

Phase 1

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborators:

Blood Cancer Research Partnership
TG Therapeutics, Inc.
The Leukemia and Lymphoma Society